Antibodies in epilepsy

Current Neurology and Neuroscience Reports

Volumn 13, Issue 5, 2013, Pages

  Correll, Cynthia M ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

AMPA; ANNA 1; Antibodies; Autoimmune; Epilepsy; GABA B; GAD; Limbic encephalitis; Ma; NMDA; Voltage gated potassium channel

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR ANTIBODY; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID ANTIBODY; ANTIBODY; AUTOANTIBODY; CYCLOPHOSPHAMIDE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HU ANTIBODY; IMMUNOGLOBULIN; MA1 ANTIBODY; MA2 ANTIBODY; METABOTROPIC RECEPTOR 5 ANTIBODY; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; STEROID; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2; GLUTAMATE RECEPTOR; MEMBRANE ANTIGEN; NERVE PROTEIN;

ARTICLE; COMPLEX PARTIAL SEIZURE; DISEASE ASSOCIATION; EPILEPSY; HUMAN; OUTCOME ASSESSMENT; PARANEOPLASTIC NEUROPATHY; PLASMAPHERESIS; PREVALENCE; RISK ASSESSMENT; SEIZURE; SIMPLE PARTIAL SEIZURE; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; IMMUNOLOGY; METABOLISM; REVIEW;

ANTIBODIES; ANTIGENS, SURFACE; EPILEPSY; GLUTAMATE DECARBOXYLASE; HUMANS; NERVE TISSUE PROTEINS; POTASSIUM CHANNELS, VOLTAGE-GATED; RECEPTORS, GLUTAMATE;

EID: 84875148230     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-013-0348-1     Document Type: Article

References (63)

1. Kwan P, Brodie MJ. Early identification of refractory epilep (Pubitemid 30075244)
2. Iorio R, Lennon V. Neural antigen-specific autoimmune disorders. Immunol Rev. 2012; 248: 104-21.
3. Bien CG, Schulz-Bonhage A, Deckert M., et al. Limbic encephalitis not associated with neoplasm as a cause of temporal lobe epilepsy. Neurology. 2000; 55: 1823-8. (Pubitemid 32103963)
4. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings, and tumor association in 50 patients. Brain. 2000; 123: 1481-94. (Pubitemid 30420947)
5. Vincent A, Irani SR, Lang B. The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Curr Opin Neurol. 2010; 23: 144-50.
6. Bien CG, Scheffer IE. Autoantibodies and epilepsy. Epilepsia. 2011; 52(3): 18-22.
7. Zuliani L, Graus F, Giometto B., et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry. 2012; 83: 638-45.
8. Irani SR, Bien CG, Lang B. Autoimmune epilepsies. Curr Opin Neurol. 2011; 24: 146-53.
9. Graus F, Saiz A, Lai M., et al. Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology. 2008; 71: 930-6.
10. Alamowitch S, Graus F, Uchuya M., et al. Limbic encephalitis and small cell lung cancer: clinical and immunological features. Brain. 1997; 120: 923-8. (Pubitemid 27259543)
11. Graus F, Keime-Guibert F, Rene R., et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001; 124: 1138-48. (Pubitemid 32510382)
12. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998; 50: 652-7.
13. Dalmau J, Graus F, Rosenblum M.K., et al. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy a clinical study of 71 patients. Medicine. 1992; 71: 59-72.
14. Rosenfeld MR, Eichen JG, Wade D.F., et al. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol. 2001; 50: 339-48. (Pubitemid 32848736)
15. Dalmau J, Graus F, Villarejo A., et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004; 127: 1831-44. (Pubitemid 39061559)
16. Mata S, Muscas GC, Naldi I, et al. Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J Neuroimmunol. 2008; 199(1-2): 155-9.
17. Blanc F, Ruppert E, Kleitz C., et al. Acute limbic encephalitis and glutamic acid decarboxylase antibodies: A reality? J Neurol Sci. 2009; 287: 69-71.
18. Malter MP, Helmstaedter C, Urbach H. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010; 67: 470-8.
19. Majoie HJM, de Baets M, Renier W, et al. Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res. 2006; 71: 135-41. (Pubitemid 44419592)
20. Vincent A, Buckley C, Schott J., et al. Potassium channel antibody-associated encephalopathy: A potentially immunotherapy-responsive form of limbic encephalitis. Brain. 2004; 127: 701-12. (Pubitemid 38295483)
21. Lai M, Huijbers MGM, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: A case series. Lancet Neurol. 2010; 9: 776-85. This study of 57patients with limbic encephalitis attributed to voltage-gated potassium channels demonstrated that the antibodies were actually binding to Lgi1 and CASPR2 antigens, proteins associated with the VGKC complex.
22. Irani SR, Alexander S, Waters P., et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010; 133: 2734-48.
23. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007; 61(1): 25-36. (Pubitemid 46214241)
24. Sansing LH, Tüzün E, Ko MW, Baccon J, Lynch DR, Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies. Nat Clin Pract Neurol. 2007; 3(5): 291-6. (Pubitemid 46745476)
25. Dalmau J, Gleichman AJ, Hughes E.G., et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008; 7: 1091-8.
26. Irani SR, Bera K, Waters P., et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010; 133: 1655-67.
27. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011; 10: 63-74.
28. Titulaer MJ, McCracken L, Gabilondo I., et al. Treatment and prognostic factors for long-term outcomes in patients with anti-NMDA receptor encephalitis: an observation cohort study. Lancet Neurol. 2013; 12: 157-65. This observation cohort study of immunotherapy outcomes on 501 patients with NMDAR encephalitis found that 81 % of patients had improvement with good outcome at 2 years. Predictors of good outcome included early initiation of treatment and initiation of second line therapy (rituximab and/or cyclophosphamide).
29. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009; 65: 424-34.
30. Bataller L, Galiano R, Garcia-Escrig M, et al. Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology. 2010; 74: 265-7.
31. Lancaster E, Lai M, Hughes E. Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterization of the antigen. Lancet Neurol. 2010; 9: 67-76. This study of 15 patients with limbic encephalitis was the first to identify GABA-B antibodies as a cause of this disorder. All 15 patients with GABA-B antibody encephalitis developed seizures with 13 of the patients noted to have seizures as their presenting symptom.
32. Boronat A, Sabater L, Saiz A., et al. GABAB receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011; 76: 795-800.
33. Lancaster E, Martinez-Hernandez E, Titulaer M.J., et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology. 2011; 77: 1698-701.
34. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011; 69: 892-900. This case series described 29 patients with faciobrachial dystonic seizures. Lgi1 antibodies were found in 89 % of the patients. This seizure type showed a much poorer response to antiepileptic medications compared with immunotherapy.
35. Irani SR, Vincent A. NMDA receptor antibody encephalitis. Curr Neurol Neurosci Rep. 2011; 11: 298-304.
36. Schmitt SE, Pargeon K, Frechette E.S., et al. Extreme delta brush: A unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012; 79: 1094-100.
37. Dalmau J. Status epilepticus due to paraneoplastic and nonparaneoplastic encephalitides. Epilepsia. 2009; 50 Suppl. 12: 58-60.
38. Graus F, Boronat A, Xifro X., et al. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology. 2010; 74: 857-9.
39. Vianello M, Tavolato B, Giometto B. Glutamic acid decarboxylase autoantibodies and neurological disorders. Neurol Sci. 2002; 23: 145-51. (Pubitemid 35345488)
40. Giometto B, Nicolao P, Macucci M., et al. Temporal-lobe epilepsy associated with glutamic-acid-decarboxylase autoantibodies. Lancet. 1998; 352: 457. (Pubitemid 28362802)
41. Peltola J, Kulmala P, Isojarvi J., et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology. 2000; 55(1): 46-50. (Pubitemid 30460996)
42. Errichiello L, Perruolo G, Pascarella A., et al. Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: A study on 233 patients. J Neuroimmunol. 2009; 211(1-2): 120-3.
43. Errichiello L, Striano S, Zara F., et al. Temporal lobe epilepsy and anti-glutamic acid decarboxylase autoimmunity. Neurol Sci. 2011; 32: 547-50.
44. Liimatainen S, Peltola M, Sabater L., et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia. 2010; 51(5): 760-7.
45. Falip M, Carreno M, Miro J., et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol. 2012; 19: 827-33. This study examined the prevalence of GAD65 antibodies in 42 patients with adult onset temporal lobe epilepsy, 19 with known etiology and 23 with unknown etiology. GAD65 antibodies were present in 21 % of the patients (8.7 % high titers) with unknown etiology of their epilepsy.
46. Porta-Etessam J., Ruiz-Morales J, Millan J.M., et al. Epilepsia partialis continua and frontal features as a debut of anti-Hu paraneo-plastic encephalomyelitis with focal frontal encephalitis. Eur J Neurol. 2001; 8: 359-60. (Pubitemid 32612900)
47. Shavit YB, Graus F, Probst A., et al. Epilepsia partialis continua: A new manifestation of anti-Hu-associated paraneoplastic encephalomyelitis. Ann Neurol. 1999; 45: 255-8. (Pubitemid 29072374)
48. Rudzinskia LA, Pittockb SJ, McKeon A, et al. Extratemporal EEG and MRI findings in ANNA-1 (anti-Hu) encephalitis. Epilepsy Res. 2011; 95: 255-62.
49. McKnight K, Jiang Y, Hart Y., Cavey A, Wroe S, Blank M., et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology. 2005; 65: 1730-6.
50. Niehusmann P, Dalmau J, Rudlowski C., et al. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol. 2009; 66(4): 458-64.
51. Bien CG, Elger CE. Limbic encephalitis: A cause of temporal lobe epilepsy with onset in adult life. Epilepsy Behav. 2007; 10: 529-38. (Pubitemid 46768031)
52. Keime-Guibert F., Graus F, Fleury A., et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, Anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000; 68(4): 479-82. (Pubitemid 30248748)
53. Battaler L, Kleopa KA, Wu G.F., et al. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry. 2007; 78: 381-5. (Pubitemid 46580546)
54. Gabilondo I, Saiz A, Galán L, et al. Analysis of relapses in anti-NMDAR encephalitis. Neurology. 2011; 77: 996-9.
55. Irani SR, Buckley C, Vincent A., et al. Immunotherapy-responsive seizure-like episodes with potassium channel antibodies. Neurology. 2008; 71: 1647-8.
56. Kaymakamzade B, Kansu T, Tan E., et al. LGI1 related limbic encephalitis and response to immunosuppressive therapy. J Neurol. 2011; 258: 2075-7.
57. Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012; 69(5): 582-93. This case series of 32patients with autoimmune antibody-mediated epilepsy treated with immunotherapy reported an improvement rate of 81 %, with 18 patients becoming seizure free. Patients who showed improvement had a significantly shorter time to therapy initiation than patients who did not respond to therapy, at 4 months and 22 months respectively.
58. Scheid R, Lincke T, Voltz R., et al. Serial 18F-fluoro-2-deoxy-D-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis. Arch Neurol. 2004; 61: 1785-9. (Pubitemid 39463437)
59. Ances BM, Vitaliani R, Taylor R.A., et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain. 2005; 128(8): 1764-77. (Pubitemid 41373648)
60. Fauser S, Talazko J, Wagner K., et al. FDG-PET and MRI in potassium channel antibody-associated non-paraneoplastic limbic encephalitis: correlation with clinical course and neuropsychology. Acta Neurol Scand. 2005; 111: 338-43. (Pubitemid 40559411)
61. Urbach H, Soeder BM, Jeub M, et al. Serial MRI of limbic encephalitis. Neuroradiology. 2006; 48: 380-6. (Pubitemid 43923159)
62. Bien CG, Urbach H, Schramm J., et al. Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology. 2007; 69: 1236-44. (Pubitemid 47429024)
63. Titulaer MJ, Soffietti R, Dalmau J., et al. Screening for tumors in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011; 18: 19-27.